PER
Percheron Therapeutics Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-18.39%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
6
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
📈 Performance
Price History
-91.67%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PER
6
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
19 weeks
💵 Average investment amount
$1,612
⏰ Last time a customer invested in PER
5 days
PER investor breakdown
💵 Income of investors
More than 200k
11%
150k - 200k
11%
100k - 150k
33%
50k - 100k
11%
Less than 50k
22%
👶 Age of investors
18 - 25
26 - 34
33%
35 - 90
67%
🙋 Legal gender of investors
Female
17%
Male
83%
Pearlers who invest in PER also invest in...
NDQ
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
27.66%
📊 Share price
$50.95 AUD
🇺🇸 UNITED STATES
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
Adairs Ltd. is engaged in retail operations in thef manchester and homewares. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-06-17. The firm has three vertically integrated brands, Adairs, Mocka, and Focus on Furniture. Its brands sell in-house designed products direct to customers in Australia and New Zealand. Adairs is a specialty omni-channel retailer of home furnishings in Australia and New Zealand with a national footprint of stores across various formats and an online channel. Mocka is a vertically integrated pure-play online home and living products designer and retailer operating in Australia and New Zealand. Mocka sells its own products in the home furniture and decor, kids, and baby categories. Focus on Furniture (Focus) is a vertically integrated omni-channel furniture and bedding retailer offering products through its network of stores in Australia and its online channel.
🙌 Performance (5Yr p.a)
3.16%
📊 Share price
$2.64 AUD
🕊️ SOCIALLY AWARE
💰 HIGH DIVIDEND
🛍️ CONSUMER
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
14.02%
📊 Share price
$140.20 AUD
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
🌏 GLOBAL
🤖 TECHNOLOGY
Accent Group Ltd. operates as an investment holding company, which engages in the retail of performance and lifestyle footwear. The company is headquartered in Richmond, Victoria. The company went IPO on 2004-07-07. The firm operates approximately 786 stores and approximately 35 Websites across different retail banners, and distribution rights for 17 international brands across Australia and New Zealand. The firm's geographical segments include Australia and New Zealand. The Company’s banners and brands include The Athlete’s Foot (TAF), Platypus Shoes, Hype DC, Skechers, Merrell, CAT, Vans, Dr. Martens, Saucony, Timberland, HOKA, Superga, Kappa, Palladium, Supra, Subtype, The Trybe, Stylerunner, Glue Store, Autry, and UGG. Its subsidiaries include The Athlete's Foot Australia Pty Ltd, RCG Brands Pty Ltd, RCG Retail Pty Ltd, TAF eStore Pty Ltd, Accent Store Development Pty Ltd, Hype DC Pty Ltd, Subtype Pty Ltd, Accent Active (NZ) Limited, TAF Hornsby Pty Ltd, and Accent Lifestyle (NZ) Limited.
🙌 Performance (5Yr p.a)
4.25%
📊 Share price
$2.34 AUD
🛍️ CONSUMER
💰 HIGH DIVIDEND
📈 HIGH PRICE GROWTH
Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The firm's principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. The firm's other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users.
🙌 Performance (5Yr p.a)
-13.20%
📊 Share price
$0.06 AUD
🩺 HEALTH CARE
Want more shares? Try these...
Phoslock Environmental Technologies Ltd. is a global water technology company which engages in the manufacture and sale of environmental solutions. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-08-16. The firm is specialized in engineering solutions and water treatment products to remediate polluted lakes, rivers, canals and drinking water reservoirs. The company has four operating segments based on geographical areas, such as Australia/NZ, Europe/The United Kingdom, United States/Canada/Brazil, and China. The Company’s products include Phoslock and Phosflow. Phoslock is a proprietary water treatment product that permanently binds excess phosphorus in the water column and sediments and enables it to settle in an environmentally benign state. Along with Phoslock, the Company also supplies zeolites and specialized solutions that address water pollution issues. Phosflow absorbs phosphorus from water upon contact. Phosflow is used in wastewater effluents including municipal, industrial, and agricultural wastewaters. Phosflow can be packaged into various vessels and chambers, as well as water permeable containers.
🙌 Performance (5Yr p.a)
-19.37%
📊 Share price
$0.03 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
Peninsula Energy Ltd. engages in the mining, exploration, and development of uranium properties. The company is headquartered in Subiaco, Western Australia. The firm owns the Lance Project (Lance) and Dagger Project. The Lance Project is located in Wyoming, United States of America, operated through its 100% owned subsidiary, Strata Energy Inc (Strata). The Lance Projects comprise the Ross Production Project Area, Kendrick Development Project Area and Barber Exploration Area. The Lance Projects are located in Crook County, in northeastern Wyoming, approximately 31 miles east-northeast of the town of Gillette and extend over a strike length of 37 kilometers (kms) to the north, and over a strike width of eight km. The company holds mineral rights and surface access rights over a non-contiguous north-south distance of about 50 km. The company has mineral rights over 34,068 acres and surface access rights over land holdings 8,426 acres. The Dagger Project in Crook County, Wyoming lies within the North Black Hills district in the northeast corner of the state.
🙌 Performance (5Yr p.a)
154.33%
📊 Share price
$1.24 AUD
⚡️ ENERGY
